Sandra Milligan, M.D., J.D.
Board Member
Spyre Therapeutics, Inc. (SYRE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Sandra Milligan, M.D., J.D.
Sandra Milligan, M.D., J.D. is recorded as Board Member at Spyre Therapeutics, Inc. (SYRE). Spyre Therapeutics, Inc. reported in an 8-K filed May 15, 2024 that Sandra Milligan, M.D., J.D. was appointed Class III director, effective May 14, 2024.
“On May 14, 2024, the board of directors (the "Board") of the Company appointed Sandra Milligan, M.D., J.D. as a Class III director of the Company and as a member of the Board's compensation committee and nominating and corporate governance committee, effective immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-05-14–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Spyre Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Cameron Turtle CEO, COO, Board Member
- Cameron Turtle, DPhil CEO, Board Member
- James Kastenmayer CEO
- Jeffrey M. Goldberg CEO
- Scott Burrows CFO, Chief Accounting Officer
- Heidy Abreu King-Jones General Counsel
- Jonathan Alspaugh Chief Accounting Officer
- Steven Weber Chief Accounting Officer
- Jeffrey Albers Board Member
- Laurie Stelzer Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.